Treating the PAH Patient in Primary Care

Pulmonary Disease
Optimizing PAH Therapy to Improve Patient Outcomes in the Primary Care Setting
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
August 23, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Primary Care Physicians

Relevant Terms:

Richard N. Channick, MD

​Richard N. Channick, MD
Director of the Pulmonary Hypertension and Thromboendarterectomy Program 
Massachusetts General Hospital
Associate Professor of Medicine 
Harvard Medical School
Boston, MA

Richard Channick, MD, is Director of the Pulmonary Hypertension and Thromboendarterectomy Program at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Channick received his medical degree at Temple University Medical School, where he was elected to the Alpha Omega Alpha Medical Honor Society.  He did his residency and was Chief Resident at the University of Massachusetts Medical Center.  He did a pulmonary and critical care fellowship at the University of California, San Diego Medical Center.  Dr. Channick has published over 200 original articles, chapters and reviews focused on all aspects of pulmonary hypertension and pulmonary embolism. He serves on many national and international leadership committees including the American Thoracic Society Pulmonary Circulation Program Committee and the American College of Chest Physicians Pulmonary Vascular Disease Network steering committee. Past Chair of the Scientific Leadership Committee and current Vice Chair of the Pulmonary Hypertension Care Center's Board of Directors for the Pulmonary Hypertension Association.  He is also President Elect of the National Pulmonary Embolism Response Team (PERT) Consortium.  Dr. Channick has served on the steering committees for several pivotal clinical trials in pulmonary hypertension and lectures nationally and internationally.

Vallerie V McLaughlin, MD, FACC, FAHA, FCCP

Vallerie V McLaughlin, MD, FACC, FAHA, FCCP 
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine 
Director of Pulmonary Hypertension Program 
Associate Chief, Cardiovascular Medicine 
Director, Heart Vessel Blood Clinical Trials Support Unit 
Director, Disease Management Ambulatory Care Unit 
Director, Inpatient Services University of Michigan 
Ann Arbor, MI

Vallerie V. McLaughlin, MD, is the Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Director of the Pulmonary Hypertension Program, and Associate Chief of Cardiovascular Medicine at the University of Michigan, Ann Arbor. She is a Fellow of the American College of Cardiology, the American College of Chest Physicians and the American Heart Association, and is a member of the American Thoracic Society. She has served as Chair of the American Heart Association "Women in Cardiology" Committee and as a member of the American College of Cardiology Scientific Sessions Program Committee. Professor McLaughlin is a Past-Chair of the Scientific Leadership Council of the PH Association, Past-Editor-in-Chief of Advances in Pulmonary Hypertension. and Past-Chair of the PH Association Board of Trustees.She was Chair of the American College of Cardiology/American Heart Association Clinical Expert Consensus Document on PH. She was inaugurated as a charter member into the Clinical Excellence Society at the University of Michigan. Her research interests focus on PH.
1. Review the current strategies for the management of pulmonary arterial hypertension with a focus on new options
2. Identify strategies for improving outcomes in patients with pulmonary arterial hypertension with specific attention to long-term outcomes and predictors of disease progression

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Method of Participation Statements of credit will be awarded based on the participant reviewing the entire presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at
Faculty Disclosures
Dr. Channick has disclosed the following relevant financial relationships:
Consultant: Actelion, Arena, Bayer
Contracted Research: Actelion, Bayer, Gilead 
Dr. McLaughlin has disclosed the following relevant financial relationships:
Consultant - Actelion, Arena, Bayer, Medtronic, Merck, United Therapeutics
Contract Research - Actelion, Eiger, Sonovie
Accredited Provider Disclosure
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Patricia Brignoni, AKH Director of Operations: has disclosed no relevant financial relationships.

Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.
AKH Inc, planners and reviewers have disclosed no financial relationships with pharmaceutical or medical product manufacturers.
Commercial Support 
This activity is supported by an educational grant from Actelion Pharmaceuticals.
There is no fee to participate in this activity
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
Copyright © 2018 No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publishe
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.